MBX Biosciences (MBX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on MBX Biosciences (MBX) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.03 of bullish evidence against -0.26 bearish.

MBX Biosciences last closed at $56.92, -2.77% on the session.

Against the IVW growth benchmark the position is -3.38% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

MBX Biosciences has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks MBX Biosciences in the 25th percentile on return on equity, where 100 is best.

MBX Biosciences is classified under Health Care / Pharmaceuticals, with a market capitalisation of $2.82B.

StockMap tracks MBX Biosciences as the 31st largest of the 142 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 61 Moderate Underperform, 57 Neutral, 19 Strong Underperform and 5 Moderate Outperform.

On that composite MBX Biosciences ranks 63rd of 142 in the group, against a group median of -0.24.